TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01667575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: antisecretary drug of the quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: antisecretary drug of the quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: antisecretary drug of the quadruple therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: antibiotic of the quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: antibiotic of the quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: antibiotic of the quadruple therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: antibiotic of the quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: antibiotic of the quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: antibiotic of the quadruple therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: one of a component of a quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: one of a component of a quadruple therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: long duration (14 day)
Study: NCT03560193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2%Chlorhexidine-70%Isopropanol
Description: 2% Chlorhexidine-70% isopropanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5%Povidone Iodine- 69%Ethanol
Description: 5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
Study: NCT02968043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapeutic scoliosis specific exercises
Description: Physiotherapeutic scoliosis specific exercises (PSSE) is recommended as a first step in the treatment of AIS to halt curve progression by SOSORT guidelines. The PSSE program will be personalized according to the subject's curves characteristics. The program includes patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living. A physiatrist will give a detailed explanation of the aims, importance, methods, and procedure of an intervention to patients and their parents. Each subject will receive guidance from multiple physiotherapists to ensure that the treatment effects are the result of the protocol and not any particular physiotherapists.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: generalised physiotherapy exercises
Description: Generalised physiotherapy exercises includes stretching and strengthening activities. Little evidence is in favor of generalised physiotherapy exercises. Each subject will receive guidance from multiple physiotherapists.
Study: NCT05052775

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Mouthwash
Description: Patients were given chlorhexidine mouthwash 2 times per day for 15 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morus Alba 20%
Description: Patients were given morus alba 20% concentration 2 times per day for 15 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morus Alba 30%
Description: Patients were given morus alba 30% concentration 2 times per day for 15 days
Study: NCT02941107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotarix (RV1)
Description: ROTARIX™ (RV1) is a live-attenuated human monovalent oral vaccine containing attenuated G1P\[8\] human rotavirus strain sponsored and distributed in Australia by GlaxoSmithKline Biologicals where it is licensed for the prevention of rotavirus gastroenteritis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo for this trial will be Viscosweet, a clear and flavoured solution used as a pharmaceutical excipient repackaged into a labelled syringe identical to the active and firmly sealed with an end cap.
Study: NCT03116399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISM 2.0 Condition
Description: Access to the PRISM 2.0 program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Tablet Condition
Description: Access to the tablet
Study: NCT04075201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One dose of investigational vaccine
Description: One dose of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research \& Development Co., Ltd.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One dose of investigational vaccine
Description: One dose of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research \& Development Co., Ltd.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: One dose of control vaccine
Description: One dose of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of investigational vaccine
Description: Three doses of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research \& Development Co., Ltd. on the schedule of month 0,1,2

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three doses of control vaccine
Description: Three doses of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
Study: NCT00431847

Intervention type: PROCEDURE
Intervention: Regional Anesthesia
Description: Subject received regional anesthesia to affected limb(s) within 72 hours of traumatic event.

Intervention type: PROCEDURE
Intervention: Standard Pain Management Protocol
Description: Intermittent dosing of analgesics and anxiolytics instituted prior to continuous intravenously dosing which was individually titrated to patient care goals.
Study: NCT00905307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: oral, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: oral, once daily
Study: NCT00195728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen on Extended Release
Description: 2 tablets twice daily
Study: NCT02246764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02%
Description: 1 drop once daily (QD), PM, OU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02% BID
Description: 1 drop BID, AM/PM, OU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate Ophthalmic Solution 0.5% BID
Description: 1 drop BID, AM/PM, OU

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 drop QD, AM, OU
Study: NCT01640080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Type= exact number, number= 0.20, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.20 mg/kg administered on Day 1 and Day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Type= exact number, number= 0.40, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.40 mg/kg administered on Day 1 and Day 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= intravenous infusion, route= intravenous use. One single placebo intravenous infusion administered on Day 1 and Day 4.
Study: NCT03731429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: prior to extubation
Study: NCT03515720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: It consists of injecting 5% dextrose in sterile aqueous solution without the use of lidocaine in a subcutaneous nerve to inhibit neurogenic inflammation and the release of substance P and CGRP, decreasing neurogenic inflammation.
Study: NCT03731429

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Prior to extubation
Study: NCT01585025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Description: Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Description: Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Description: Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.
Study: NCT00890760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP
Description: 5 x 10\*10 vp IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP
Description: 5 x 10\*10 vp IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP
Description: 5 x 10\*10 vp IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP
Description: 5 x 10\*10 vp IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP
Description: 5 x 10\*10 vp IM
Study: NCT03553446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: children receiving sevoflurane
Description: Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
Study: NCT04699669

Intervention type: DRUG
Group type: OTHER
Intervention: CBL-514, placebo
Description: One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized.~No PK samples will be collected in this cohort.
Study: NCT00890760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA ME-TRAP
Description: 2 x 10\*8 pfu ID
Study: NCT04699669

Intervention type: DRUG
Group type: OTHER
Intervention: CBL-514, placebo
Description: One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized.~No PK samples will be collected in this cohort.

Intervention type: DRUG
Group type: OTHER
Intervention: CBL-514, placebo
Description: One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized.

Intervention type: DRUG
Group type: OTHER
Intervention: CBL-514, placebo
Description: One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized.

Intervention type: DRUG
Group type: OTHER
Intervention: CBL-514, placebo
Description: One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514
Description: Both sides of the abdominal region will receive CBL-514.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514
Description: Both sides of the abdominal region will receive CBL-514.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514
Description: Both sides of the abdominal region will receive CBL-514.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514
Description: Both sides of the abdominal region will receive CBL-514.
Study: NCT01771900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Camp Group
Description: In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Group
Description: Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
Study: NCT04621708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Left DLPFC iTBS rTMS
Study: NCT03722433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigiis 101-LAB and sequential therapy
Description: Vigiis 101-LAB is the probiotic containing Lactobacillus paracasei subsp. Paracasei, which is the isolate from Taiwanese by Prof. Pan. This strain is resistant to gastric acid and bile acid. Therefore, its survival rate in the gastrointestinal tract could be as high as 95%. Previous studies showed that Vigiis 101-LAB can modulate the gut microbiota, with 10% increase in Bifidobacterium species and 20% reduction in Clostridium difficile.
Study: NCT00890760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA ME-TRAP
Description: 2 x 10\*8 pfu ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA ME-TRAP
Description: 2 x 10\*8 pfu ID
Study: NCT02446054

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Musashino T2DM diet
Description: provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
Study: NCT00076219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal replacement therapy
Description: renal replacement therapy
Study: NCT00890760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sporozoite challenge
Description: Infected mosquito bite

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sporozoite challenge
Description: Infected mosquito bite

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sporozoite challenge
Description: Infected mosquito bite

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sporozoite challenge
Description: Infected mosquito bite
Study: NCT03722433

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and sequential therapy
Description: Placebo without Vigiis 101-LAB component
Study: NCT03261661

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading
Description: Students are taught the processes involved in hearing, seeing, and feeling sounds as well as differences between sounds in words. New knowledge is built on previous knowledge in a step-by-step manner. Sounds build to letter-sound relationships to reading of words and syllables. Students learn the connection between reading of words (decoding) and writing/spelling words (encoding) building from simple words to multisyllabic words to text reading with fluency and understanding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading
Description: Students are taught the processes involved in hearing, seeing, and feeling sounds as well as differences between sounds in words. New knowledge is built on previous knowledge in a step-by-step manner. Sounds build to letter-sound relationships to reading of words and syllables. Students learn the connection between reading of words (decoding) and writing/spelling words (encoding) building from simple words to multisyllabic words to text reading with fluency and understanding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading
Description: Students are taught the processes involved in hearing, seeing, and feeling sounds as well as differences between sounds in words. New knowledge is built on previous knowledge in a step-by-step manner. Sounds build to letter-sound relationships to reading of words and syllables. Students learn the connection between reading of words (decoding) and writing/spelling words (encoding) building from simple words to multisyllabic words to text reading with fluency and understanding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindset
Description: Blended learning program with online and teacher-directed activities related to how the brain functions, learns, and remembers, and how it changes in a physical way when we exercise it. Instruction in how students are in control of their brain and its development, and how to apply this to their schoolwork with practical strategies for tackling academic challenges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindset
Description: Blended learning program with online and teacher-directed activities related to how the brain functions, learns, and remembers, and how it changes in a physical way when we exercise it. Instruction in how students are in control of their brain and its development, and how to apply this to their schoolwork with practical strategies for tackling academic challenges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Embedded with Mindset
Description: Mindset training explicitly linked to the reading content through lesson openers, feedback prompts, and self-monitoring of mindset during reading work.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Business as Usual
Description: Reading interventions already provided to students with reading difficulties as per typical procedures at the participating school
Study: NCT02524444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine
Description: Tabs Mefloquine 250mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-Pyrimethamine
Description: Sulphadoxine 500mg , Pyrimethamine 25mg
Study: NCT03100162

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01632930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)
Description: urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)
Description: urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.
Study: NCT00941356

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-K+ CL1285
Description: 2 capsules per day before breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules per day before breakfast
Study: NCT02987335

Intervention type: DRUG
Intervention: Pancreatic Clamp
Description: We are not performing any interventions; we are only characterizing participants using tests. The hormones that we are administering are not a treatment but are typically used in context of routine care.

Intervention type: DRUG
Intervention: Pancreatic Clamp
Description: We are not performing any interventions; we are only characterizing participants using tests. The hormones that we are administering are not a treatment but are typically used in context of routine care.

Intervention type: DRUG
Intervention: Pancreatic Clamp
Description: We are not performing any interventions; we are only characterizing participants using tests. The hormones that we are administering are not a treatment but are typically used in context of routine care.
Study: NCT00837616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 B estradiol orally
Description: Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 B estradiol
Description: Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
Study: NCT00076219

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: renal replacement therapy
Description: renal replacement therapy
Study: NCT02154802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video: community member

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video: physician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video: choice of video